These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 27642533)
21. Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis. Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio MP; Wan GJ J Health Econ Outcomes Res; 2022; 9(1):90-100. PubMed ID: 35529249 [No Abstract] [Full Text] [Related]
22. [Inflammatory myopathies. Dermatomyositis, polymyositis, and inclusion body myositis]. Selva O'Callaghan A; Trallero Araguás E Reumatol Clin; 2008 Sep; 4(5):197-206. PubMed ID: 21794530 [TBL] [Abstract][Full Text] [Related]
23. Inflammatory myopathies: evaluation and management. Greenberg SA Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525 [TBL] [Abstract][Full Text] [Related]
24. [Pathogenesis of polymyositis and dermatomyositis]. Morović-Vergles J; Mitrović J Reumatizam; 2012; 59(2):23-6. PubMed ID: 23745450 [TBL] [Abstract][Full Text] [Related]
25. Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study. Judson MA; Modi A; Ilyas F; Yucel R Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(3):192-197. PubMed ID: 32476902 [No Abstract] [Full Text] [Related]
26. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199 [TBL] [Abstract][Full Text] [Related]
27. [Dermatomyositis and polymyositis: clinical aspects and treatment]. Hachulla E Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087 [TBL] [Abstract][Full Text] [Related]
36. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Khan S; Christopher-Stine L Rheum Dis Clin North Am; 2011 May; 37(2):143-58, v. PubMed ID: 21444016 [TBL] [Abstract][Full Text] [Related]
37. Current pharmacological treatment of idiopathic inflammatory myopathies. Fasano S; Alves SC; Isenberg DA Expert Rev Clin Pharmacol; 2016 Apr; 9(4):547-558. PubMed ID: 26708717 [TBL] [Abstract][Full Text] [Related]
38. Current diagnosis and treatment of polymyositis and dermatomyositis. Sasaki H; Kohsaka H Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460 [TBL] [Abstract][Full Text] [Related]
39. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis]. Cherin P Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990 [TBL] [Abstract][Full Text] [Related]
40. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]